コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 dothelial functions in vitro, in vivo and in disease model.
2 5Y cells, a widely used in vitro Parkinson's disease model.
3 votal role in inflammation in a mouse kidney disease model.
4 as assessed in a skin challenge and invasive disease model.
5 , fatty acids and steroids in a Huntington's disease model.
6 In this study we used melanoma as a disease model.
7 onses using a severe acute graft versus host disease model.
8 ffector CD8 T cell response to an infectious disease model.
9 organ level, in a dysmotile gastrointestinal disease model.
10 ptic terminals in a murine WNV neuroinvasive disease model.
11 as well as in an in vivo inflammatory bowel disease model.
12 n antifibrotic effect of PPIs using IPF as a disease model.
13 ower of key signatures characteristic of the disease model.
14 ease model, which is the simplest multistate disease model.
15 committed to the application of the medical disease model.
16 nvestigated in a well-established alphavirus disease model.
17 tion of PNEC secretion of GABA in a neonatal disease model.
18 he development of atherosclerosis in a mouse disease model.
19 l myasthenic syndrome type 19 and serve as a disease model.
20 d treatments shown to be effective in animal disease models.
21 uction may contribute to effects observed in disease models.
22 udied both in vitro and in vivo using animal disease models.
23 cular changes upon drug treatment in various disease models.
24 thought to cause inflammation in necroptotic disease models.
25 has neuroprotective effects in Huntington's disease models.
26 protects mice from pathological bone loss in disease models.
27 ies and pathogenicity in murine inflammatory disease models.
28 trongest female-bias was found in infectious disease models.
29 ted by genetic manipulation of DNA repair in disease models.
30 of disease, and permit the use of tractable disease models.
31 ponse of mice to three distinct inflammatory disease models.
32 europrotective efficacy in many neurological disease models.
33 structure-based approach, can be assessed in disease models.
34 formation about drug activity within complex disease models.
35 operties suitable for application in in vivo disease models.
36 e observed in psychiatric illness, in animal disease models.
37 tress response factors protective in amyloid disease models.
38 on in renal cells and in experimental kidney disease models.
39 properties in ischemic stroke and Huntington disease models.
40 sed to generate patient- and tissue-specific disease models.
41 rged as a key player in various inflammatory disease models.
42 to have protective effects in several renal disease models.
43 s therapeutic effects in various preclinical disease models.
44 regulation or knock-out improves outcomes in disease models.
45 g towards heart failure in 2 surgery-induced disease models.
46 s, stem-cell differentiation data and animal disease models.
47 th patients with heart disease and in rodent disease models.
48 adaptive immune responses and in autoimmune disease models.
49 ice tau appropriately in order to be used as disease models.
50 d microglia of normal white matter in myelin disease models.
51 ated in autoimmune diseases and inflammatory disease models.
52 mplications of mechanistic studies in animal disease models.
53 ith an emphasis on its origin, genetics, and disease models.
54 ed, including pharmacological treatments and disease models.
55 nctional reorganization of brain circuits in disease models.
56 evelopment of personalized, in vitro cardiac disease models.
57 role of the inflammasome in a wide range of disease models.
58 is required for injury responses in diverse disease models.
59 expression patterns, and generation of human disease models.
60 tects oligodendrocyte lineage cells in other disease models.
61 ely alleviated symptoms in mouse Parkinson's disease models.
62 acterization and validation in complementary disease models.
63 em cell biology to regenerative medicine and disease modeling.
64 pplications such as early drug screening and disease modeling.
65 ts an important tool in drug development and disease modeling.
66 t utility in regenerative medicine and human disease modeling.
67 n for their use in clinical applications and disease modeling.
68 for recapitulating human gene expression and disease modeling.
69 despread in vitro models for development and disease modeling.
70 drug testing, high-throughput screening, and disease modeling.
71 ental platforms that may be instrumental for disease modeling.
72 vis as a subject for biological research and disease modeling.
73 ing the production of genome-edited pigs for disease modeling.
74 d, creating a rich public resource for human disease modelling.
75 s a new strategy for tissue regeneration and disease modelling.
76 rdiomyocytes are well established as cardiac disease model..
77 of TR1 cells in a murine inflammatory bowel disease model, a model that resembles the trials perform
80 that the diabetic ob/ob genotype and the MCD disease model alter kidney transporter expression and al
81 ting Tregs in a xenogeneic graft-versus-host disease model and in adoptive transfer models of experim
82 the initialization and parametrization of a disease model and show that this allows us to determine
83 on characteristics in a transient arrhythmia disease model and subsequent tissue self-adaptation.
92 for deriving human COs, which can be used in disease modeling and drug discovery for colorectal disea
93 luripotent stem cells (hiPSCs) are useful in disease modeling and drug discovery, and they promise to
100 broad applications for cholangiopathies, in disease modeling and for screening of therapeutic compou
101 us, PSC-derived AEC2s provide a platform for disease modeling and future functional regeneration of t
102 o explore how this new culture system allows disease modeling and gene repair for a personalized rege
103 gineering of macroscale human myocardium for disease modeling and heart repair from embryonic and ind
104 eed for a paradigm shift towards integrative disease modeling and neuroimaging biomarker-guided preci
105 ers unprecedented opportunities for in vitro disease modeling and personalized cell replacement thera
109 uripotent stem cell (PSC)-derived neurons in disease modeling and regenerative medicine requires anal
114 duced pluripotency is a promising avenue for disease modeling and therapy, but the molecular principl
121 This study emphasises the value of PSCs for disease modelling and underlines the significance of in
124 this review article, we introduce multistate disease models and competing risks analysis and explain
125 to Parkinson's disease-like damage in rodent disease models and considered in clinical association st
126 ses of stem cell science to generate precise disease models and designer cell samples for personalize
127 ssection of canonical NF-kappaB signaling in disease models and healthy tissues, the success of the s
128 greatly reduced in samples from Huntington's disease models and in Huntington's disease patients, and
130 ge-guided FE method can be extended to other disease models and is amenable to clinical translation f
131 nhibition is beneficial in neurodegenerative disease models and its effects are often attributable to
132 clear in part due to the lack of appropriate disease models and the absence of a simple method for th
133 est male-bias was observed in cardiovascular disease models and the strongest female-bias was found i
136 s a scalable cell source for drug discovery, disease modeling, and cardiac regenerative therapy.
141 al for use in hematopoietic cell production, disease modeling, and eventually transplantation medicin
145 re suitable for in vitro myelination assays, disease modeling, and screening of pharmacological compo
146 man responses are needed for drug screening, disease modeling, and, ultimately, kidney organ engineer
147 ajor impacts on the predictions of behaviour-disease models, and further study of such processes in t
148 g, help define disease mechanisms, establish disease models, and provide a basis for translational re
152 is heterogeneous group of diseases, adequate disease models are required in order to better understan
153 de dose range in the cotton rat RSV enhanced-disease model, as suboptimal dosing of several RSV F sub
155 high-content screening of various C. elegans disease models at the speed and cost of in vitro cell-ba
156 advances in the research fields of genetics, disease modelling, biomarkers, and therapeutic strategie
157 quantitative group comparisons of normal and disease model brain cells for the whole brain at a high
158 vivo mechanistic model and a chronic in vivo disease model but suffers from tolerability issues upon
162 We show in a Chinese hamster ovary (CHO) disease model cell line and mouse embryonic stem (ES) ce
164 ting one of the earliest defects observed in disease models, contributing to denervation and motoneur
165 The cohort was considered as a multistate disease model, cumulative incidences (CumIs) of events w
166 pplication of cardiac tissue engineering for disease modeling, drug development, and cardiac repair.
167 ngle-cell level, which should be valuable to disease modeling, drug discovery, and preclinical cardio
168 constitute a potential cell source for heart disease modeling, drug screening, and cell-based therape
170 nal mutagenesis should have broad utility in disease modeling, drug screening, and regenerative medic
171 nes for myogenic genes which can be used for disease modeling, drug screening, gene correction and fu
172 PSCs, hold great potential for personalized disease modeling, drug testing and cell-based therapeuti
174 nate immunity, we exploited a unique mucosal disease model, endometritis, where inflammation is a con
176 EIVPD was related to the severity of liver disease (Model for End-Stage Liver Disease, rho = 0.45,
177 ompound heterozygous architectures, a common disease model for recessive monogenic disorders, where t
179 role in these diseases and provide tractable disease models for further investigation, we analyzed th
180 main focus is on the creation of new primate disease models for understanding the pathological mechan
181 ophila galactosemia I (dGALT) and II (dGALK) disease models genetically interact; manifesting deficit
184 their application in tissue engineering and disease modeling have great potential to advance innovat
185 e period, useful mouse and non-human primate disease models have been established, and pre-clinical e
187 licable to other developmental questions and disease models, highlighting the power of relatively sma
188 been shown to be expressed on DCs in several disease models, however, its role in asthma is yet to be
189 tion suppressed pathological angiogenesis in disease models, identifying MAP4K4 as a potential therap
191 ly members, prioritizing variants assuming a disease model, imputation of untyped variants, and linka
195 it an ideal platform for drug discovery and disease modelling in the fields of human neurodegenerati
196 vances have been made in terms of developing disease models in animals, such as transgenic mice, many
197 nology has been used widely to develop human disease models in laboratory animals and to study gene f
198 s tools can identify phenotypically relevant disease models in research and diagnostic contexts.
200 and protective effects when administered in disease models, in part, by reducing neutrophil infiltra
201 in neurodegenerative and other inflammatory disease models including chronic obstructive pulmonary d
202 and physiology than 2D cultures for numerous disease models, including cancer and polycystic kidney d
206 results obtained with mouse neutrophils (and disease models) into enhanced understanding of human inf
207 ng a comprehensive integrated approach to ID disease modeling, involving human cellular analyses coup
210 Testing potential drug treatments in animal disease models is a decisive step of all preclinical dru
211 y of Mesp1-CPCs in cell culture and ischemic disease models is an important initial step toward using
212 acodynamic activity, and efficacy in chronic disease models is beneficial for enabling hypothesis-dri
213 recent rapid adoption of zebrafish as human disease models is making management of these data partic
214 18)F]BF4(-)-PET combined with NIS expressing disease models is particularly useful whenever preclinic
215 or bioengineering, cell transplantation, and disease modeling, it would be useful to establish those
216 ound 1a showed promising efficacy in several disease models, its binding to a H3 receptor as well as
218 to study disease progression in a multistate disease model may be called competing risks analysis, na
219 inopathies and indicates that human midbrain disease models may be useful for identifying critical th
220 cholinergic receptor expression in Alexander disease model mice and in postmortem brain tissue from A
221 t blocking muscarinic receptors in Alexander disease model mice reduces oxidative stress, emphasizing
225 f1) Although induced in in vivo Huntington's disease models, NPM1 protein levels are unchanged in cul
228 an experimental autoimmune encephalomyelitis disease model of neurodegeneration in multiple sclerosis
229 RGCs from hESCs, allowing future studies on disease modeling of optic neuropathies and development o
232 isplayed therapeutic benefits in preclinical disease models of hemophagocytic lymphohistiocytosis and
234 TPD significantly attenuated TACE-mediated disease models of sepsis, rheumatoid arthritis (RA) and
236 target for intervention in ALS patients and disease models, our data indicate that the melanocortin
238 ), have shown therapeutic effects in several disease models, prompting us to determine whether DMF is
239 bustness to mutation has had major impact on disease models, quantitative genetics, and evolutionary
240 presents a common denominator among multiple disease models ranging from cells to humans through mous
242 s, and our methods are applicable to various disease models regardless whether the underlying true mo
243 gene editing in hPSCs a more viable tool for disease modeling, regenerative medicine and cell-based t
244 logy has expanded with 3 major applications: disease modeling, regenerative therapy, and drug discove
245 al, including enhanced orthology data, Human Disease Model Reports, protein domain search and visuali
246 r, administration of Bis-T-23 in these renal disease models restored the normal ultrastructure of pod
247 This strategy, based on linear progression disease models, resulted in selective detection of BE th
248 kidneys from previously examined murine NCGN disease models revealed NF-kappaB activation in affected
251 pmental studies, and can further be used for disease modeling, small molecules and genetic screens, o
254 yocytes (hiPSC-CMs) for drug development and disease modeling studies, methods to generate large, fun
256 vo potential functions of PAK4 in pancreatic disease models such as for pancreatitis and different pa
257 n (VNS) is effective in various inflammatory disease models, such as rheumatoid arthritis and inflamm
258 tcomes in all three interacting galactosemia disease models, suggest that Futsch homolog MAP1B and th
259 ibition confers resistance in various animal disease models, suggesting that inflammation caused by n
260 rity of P. aeruginosa mutants varied between disease models, suggesting that virulence is dependent o
261 stic studies using Itpkc-deficient mice in a disease model support the genomic, cellular, and clinica
262 y, these experiments establish a progressive disease model that can contribute toward identifying the
263 acilitated the development of human cellular disease models that can be used to study pathogenesis an
264 authors describe human chronic inflammatory disease models that can help elucidate the pathophysiolo
265 been hampered for decades by the paucity of disease models that integrate molecular and functional e
266 rences in genetic background to build richer disease models that more accurately reflect the level of
268 n the R6/2 mouse, a widely used Huntington's disease model, that integration of a rearranged transgen
270 -the-art in both mechanistic and correlative disease modelling, the data driving these models, the ve
273 models for mechanistic biological research, disease modelling, therapeutic target identification, dr
276 generally, we argue that bvFTD constitutes a disease model to study the neurocircuitry of complex beh
277 lying an environmentally mediated infectious disease model to the 1993 Milwaukee Cryptosporidium outb
278 d cell-ablation method was tested in several disease models to study immune cell functionalities, hep
280 ced monosodium urate-mediated peritonitis, a disease model used for studying the consequences of NLRP
283 erimental autoimmune encephalomyelitis (EAE) disease model, we found that OX40 stimulation inhibited
284 g natural killer/T-cell lymphoma (NKTL) as a disease model, we found that phosphorylation of EZH2 by
288 his approach can be extended to other animal disease models where macrophages are implicated and has
289 ks analysis, named after the competing risks disease model, which is the simplest multistate disease
290 l phenotypes onto TRN dysfunction in a human disease model, while also identifying molecular and circ
292 ithm of odds score = 3.9), under a recessive disease model with 100% penetrance and a risk allele fre
293 n an attempt to create a liver developmental disease model with a similar phenotype to Alagille syndr
294 mouse genes, gene functions, phenotypes and disease models with a strong emphasis on the relationshi
295 ward, better integration of dynamic, spatial disease models with approaches from movement ecology, la
298 . aureus infections across mouse strains and disease models with roles for signaling pathways involvi
299 ology, now provide a means to probe cellular disease models with unprecedented throughput and informa
300 o overcome them, and advances in preclinical disease models with which the most promising systems may
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。